Rizatriptan (Maxalt) vs Sumatriptan succinate (Zembrace SymTouch)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Migraine
Shared mechanism: 5-HT1B/1D receptor · full Migraine pipeline
Rizatriptan (Maxalt)
Marketed by Organon
NCT00897949 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial, and both rizatriptan doses significantly increased pain relief at 2 hours compared with placebo. The sources available for this trial do not report a sample-size calculation or a planned enrolment, so it cannot be confirmed that the trial was adequately powered.
Reported efficacy
Pain Relief at 2 Hours After the Initial Dose of Test Drug (2 hours after initial dose of test drug): Pain relief at 2 hours after the first dose: rizatriptan 5 mg 62% (285/457) and 10 mg 71% (322/455) vs placebo 35% (106/302), significantly higher for both doses (Teall et al., Headache 1998; CT.gov posted counts). (met)
Result source: NCT00897949
Sumatriptan succinate (Zembrace SymTouch)
Marketed by Tonix Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Migraine
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Rizatriptan (Maxalt): registry results are on file for Migraine, but their comparison mappings are not yet available.
Sumatriptan succinate (Zembrace SymTouch): registry results are on file for Migraine, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rizatriptan (Maxalt)'s landscape · Sumatriptan succinate (Zembrace SymTouch)'s landscape